At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 84 enrolled
Drug / intervention
Exenatide Once Weekly +1 moredrug
Likely dose
Exenatide Once Weekly 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Exenatide Once Weekly and Placebo for Children and Adolescent With Type 2 Diabetes. Completed, enrolled 84 participants across 35 sites in 7 countries.
Detailed Summary
The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Hungary, Israel, Kuwait, Mexico, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedMar 2012
Primary CompletionMay 2020
Study CompletionMay 2021
TodayJul 2026
First PostedMar 15, 2012
Enrollment StartDec 2, 2011
Primary CompletionMay 6, 2020
Study CompletionMay 5, 2021
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 14.3 years ago
Interventions
Exenatide Once Weeklydrug
2 mg exenatide once weekly
Placebodrug
Placebo